Disseminated Tumor Cells in Bone Marrow Assessed by TWIST1 , Cytokeratin 19, and Mammaglobin A mRNA Predict Clinical Outcome in Operable Breast Cancer Patients

• Published in: Clinical breast cancer Vol. 10; no. 5; pp. 378 - 384
• Main Authors: Tjensvoll, Kjersti, Oltedal, Satu, Farmen, Ragne K, Shammas, Fuad V, Heikkilä, Reino, Kvaløy, Jan T, Gilje, Bjørnar, Smaaland, Rune, Nordgård, Oddmund
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.10.2010
• Subjects: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor - analysis; Biomarkers, Tumor - genetics; Bone Marrow - chemistry; Bone Marrow - pathology; Breast Neoplasms - genetics; Breast Neoplasms - mortality; Breast Neoplasms - pathology; Carcinoma, Ductal, Breast - genetics; Carcinoma, Ductal, Breast - mortality; Carcinoma, Ductal, Breast - pathology; Carcinoma, Lobular - genetics; Carcinoma, Lobular - mortality; Carcinoma, Lobular - pathology; CK19; Disease-Free Survival; DTCs; Female; Gene Expression; Hematology, Oncology and Palliative Medicine; hMAM; Humans; Kaplan-Meier Estimate; Keratin-19 - analysis; Keratin-19 - genetics; Mammaglobin A; Middle Aged; Multimarker; Neoplasm Proteins - genetics; Nuclear Proteins - analysis; Nuclear Proteins - genetics; Obstetrics and Gynecology; Prognosis; Proportional Hazards Models; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger - analysis; Twist-Related Protein 1 - analysis; Twist-Related Protein 1 - genetics; Uteroglobin - genetics; DTCs; hMAM; CK19; Multimarker
• ISSN: 1526-8209; 1938-0666
• DOI: 10.3816/CBC.2010.n.050

Abstract Purpose To investigate the prognostic relevance of disseminated tumor cells (DTCs) in bone marrow (BM) assessed by a multimarker mRNA panel consisting of TWIST1 , cytokeratin 19 (CK19) and human mammaglobin A (hMAM) mRNA, in patients with early breast cancer. Patients and Methods TWIST1 (gene name: TWIST1 ), CK19 (gene name: KRT19 ), and hMAM (gene name: SCGB2A2 ) mRNA was quantitated in BM samples from 191 operable breast cancer patients by real-time reverse transcriptase polymerase chain reaction (RT-PCR). Results Using the highest relative mRNA concentration of TWIST1 in the control population as a cut-off, 5 of the 191 breast cancer patients showed elevated TWIST1 mRNA levels in their BM by real-time RT-PCR. Two of these patients experienced a systemic relapse during a median follow-up of 98 months. Combining these results with previous hMAM and CK19 mRNA quantifications in the same BM samples, 12 (40%) of the 30 patients with BM positive for at least 1 marker (multimarker positive) experienced a systemic relapse as compared with 18 (11%) of the 161 patients with multimarker-negative BMs. The patients with multimarker-positive BM had significantly shorter systemic recurrence-free survival ( P < .001, log-rank test), breast cancer-specific survival ( P < .001), and overall survival ( P = .03). The prognostic relevance of BM multimarker detection appeared to be independent of adjuvant treatment, although the difference was not statistically significant in the subgroup of patients who received adjuvant chemotherapy. Multivariate analysis demonstrated the BM multimarker panel status to be a strong independent predictor of clinical outcome. Conclusion Our results demonstrated the prognostic relevance of BM DTCs assessed by a multimarker mRNA panel consisting of TWIST1, CK19, and hMAM in operable breast cancer patients.